Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | MicrobiomeTrials← Back to trialsNCT03247088
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2017-07-30Est. Completion: 2027-12-31
Enrollment target: 74 participants Locations- M D Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Acute Myeloid LeukemiaRelapse/Recurrence
This is a multicenter, randomized, open-label, pragmatic low intervention clinical trial comparing high intensity reindu…
Brno, CzechiaEst. completion Jan 2028
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed…
Aachen, GermanyEst. completion Jul 2032